hexenoyl cap is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-01. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Caseins are a family of phosphoproteins (αS1, αS2, β, κ) that account for nearly 80% of bovine milk proteins. Caseins form soluble aggregates known as casein micelles, in which κ-casein contributes to micelle stabilization. Several models have been proposed to explain micellar organization. One model proposes that the micellar nucleus is formed from submicelles, with the periphery composed of κ-casein-rich microvillosities. Another model proposes a nucleus composed of casein-interlinked fibrils. A later model proposes that gel formation depends on dual interactions among casein molecules. All three models describe micelles as colloidal particles composed of casein aggregates surrounded by soluble κ-casein molecules.
Supercritical fluids combine useful properties of gas and liquid phases, as it can behave like both a gas and a liquid in various aspects. A supercritical fluid provides a gas-like characteristic when it fills a container and it takes the shape of the container. The motion and kinetics of the molecules are quite similar to gas molecules. On the other hand, a supercritical fluid behaves like a liquid because its density property is near liquid; thus, a supercritical fluid shows a similarity to the dissolving effect of a liquid. The result is that one can load masses, similar to those used in HPLC, on column per injection, and still maintain a high chromatographic efficiency similar to those attained in GC. Typically, gradient elution is employed in analytical SFC using a polar co-solvent such as methanol, possibly with a weak acid or base at low concentrations ~1%. The apparent plate count per analysis can be observed to exceed 500K plates per meter routinely with 5 um stationary phases. The operator uses software to set mobile phase flow rate, co-solvent composition, system back pressure and column oven temperature, which must exceed 40 °C for supercritical conditions needed to be achieved with CO2. In addition, SFC provides an additional control parameter – pressure – by using an automated static and dynamic back pressure regulator. From an operational standpoint, SFC is as simple and robust as HPLC, but fraction collection is more convenient because the primary mobile phase evaporates leaving only the analyte and a small volume of polar co-solvent.
== Identification of the mould == After structural comparison with different species of Penicillium, Fleming initially believed that his specimen was Penicillium chrysogenum, a species described by an American microbiologist Charles Thom in 1910. He was fortunate that Charles John Patrick La Touche, an Irish botanist, had just recently joined St Mary's as a mycologist to investigate fungi as the cause of asthma. La Touche identified the specimen as Penicillium rubrum, the identification used by Fleming in his publication. In 1931, Thom re-examined different Penicillium including that of Fleming's specimen. He came to a confusing conclusion, stating, "Ad. 35 [Fleming's specimen] is P. notatum WESTLING. This is a member of the P. chrysogenum series with smaller conidia than P. chrysogenum itself." From then on, Fleming's mould was synonymously referred to as P. notatum and P. chrysogenum. But Thom adopted and popularised the use of P. chrysogenum. In addition to P. notatum, newly discovered species such as P. meleagrinum and P. cyaneofulvum were recognised as members of P. chrysogenum in 1977. To resolve the confusion, the Seventeenth International Botanical Congress held in Vienna, Austria, in 2005 formally adopted the name P. chrysogenum as the conserved name (nomen conservandum). Whole genome sequence and phylogenetic analysis in 2011 revealed that Fleming's mould belongs to P. rubens, a species described by Belgian microbiologist Philibert Biourge in 1923.
Sources: en.wikipedia.org
== History == Throughout most of human history, infant nutrition has primarily depended on the availability of the child's mother or a wet nurse to breastfeed the infant. Beliefs and behaviors relating to infant feeding also vary widely across countries, cultures and times. Mothers and caregivers have also sought additional ways to feed children, sometimes referred to as "hand feeding". As early as 1500 BCE, Egyptian pottery shows images of women breastfeeding their babies and also using animal horns to feed them.
=== Evaluation of a technique === The technique being evaluated uses voltammetric sensors combined in an electronic tongue (ET) to observe the antioxidant capacity in red wines. These electronic tongues (ETs) consist of multiple sensing units like voltammetric sensors, which will have unique responses to certain compounds. This approach is optimal to use since samples of high complexity can be analyzed with high cross-selectivity. Thus, the sensors can be sensitive to pH and antioxidants. As usual, the voltage in the cell was monitored using a working electrode and a reference electrode (silver/silver chloride electrode). Furthermore, a platinum counter electrode allows the current to continue to flow during the experiment. The Carbon Paste Electrodes sensor (CPE) and the Graphite-Epoxy Composite (GEC) electrode are tested in a saline solution before the scanning of the wine so that a reference signal can be obtained. The wines are then ready to be scanned, once with CPE and once with GEC. While cyclic voltammetry was successfully used to generate currents using the wine samples, the signals were complex and needed an additional extraction stage. It was found that the ET method could successfully analyze wine's antioxidant capacity as it agreed with traditional methods like TEAC, Folin-Ciocalteu, and I280 indexes. Additionally, the time was reduced, the sample did not have to be pretreated, and other reagents were unnecessary, all of which diminished the popularity of traditional methods.
Butyl lithium (n-C4H9Li) Lithium diisopropylamide (LDA) [(CH3)2CH]2NLi Lithium diethylamide (LDEA) (C2H5)2NLi Sodium amide (NaNH2) Sodium hydride (NaH) Lithium bis(trimethylsilyl)amide [(CH3)3Si]2NLi The strongest superbases are synthesised in only gas phase:
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.